Tyme Technologies, Inc. (TYME): Price and Financial Metrics
GET POWR RATINGS... FREE!
TYME Stock Price Chart Interactive Chart >
TYME Price/Volume Stats
|Current price||$0.27||52-week high||$2.02|
|Prev. close||$0.28||52-week low||$0.22|
|Day high||$0.29||Avg. volume||799,655|
|50-day MA||$0.28||Dividend yield||N/A|
|200-day MA||$0.55||Market Cap||46.53M|
Tyme Technologies, Inc. (TYME) Company Bio
Tyme Technologies, Inc., a clinical-stage pharmaceutical company, focuses on the discovery and development of cancer therapeutics for various oncology indications. It is developing SM-88, a combination therapy in Phase II development for prostate cancer. The company was founded in 2011 and is based in New York, New York.
Most Popular Stories View All
TYME Latest News Stream
|Loading, please wait...|
TYME Latest Social Stream
View Full TYME Social Stream
Latest TYME News From Around the Web
Below are the latest news stories about Tyme Technologies Inc that investors may wish to consider to help them evaluate TYME as an investment opportunity.
Tyme Technologies Inc. (NASDAQ:TYME) shares, rose in value on Friday, 02/18/22, with the stock price down by -0.32% to the previous days close as strong demand from buyers drove the stock to $0.34. Actively observing the price movement in the last trading, the stock closed the session at $0.34, falling within a range of $0.3305 The Tyme Technologies Inc. (NASDAQ: TYME) Stock Price: Is It Overvalued? Read More »
TYME Technologies, Inc. Provides Business Update and Announces Third Fiscal Quarter 2022 Financial and Operating Results
TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™),
Tyme Technologies, Inc.''s (TYME) CEO Richie Cunningham on Q3 2022 Results - Earnings Call Transcript
No summary available.
Tyme Technologies press release (TYME): FQ3 GAAP EPS of -$0.03.The company is on track for mid-2022 full enrollment of HopES trial for SM-88 used in patients with high-risk Ewing’s…
BEDMINSTER, N.J., January 27, 2022--TYME Technologies, Inc. (Nasdaq: TYME) (the "Company" or "TYME"), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that the Company will report its third quarter 2022 financial results on Friday, February 11, 2022, at 8:30 AM ET.
TYME Price Returns